# SARS-CoV-2 Spike Trimer Protein (T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, D950N), His Tag (MALS verified)

Catalan # CDN CEOULA

#### **Synonym**

Spike, Sprotein, Spike glycoprotein, Sglycoprotein

#### **Source**

SARS-CoV-2 Spike Trimer, His Tag (SPN-C52Ha) is the ectodomain of SARS-CoV-2 spike protein which contains AA Val 16 - Pro 1213 (Accession #QHD43416.1). The mutations T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, D950N were identified in the SARS-CoV-2 Mu variant (Pango lineage: B.1.621). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.

Predicted N-terminus: Val 16

### **Molecular Characterization**

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 138 kDa. The protein migrates as 150-180 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

#### **Endotoxin**

Less than 1.0 EU per µg by the LAL method.

#### **Purity**

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

#### **Formulation**

Lyophilized from 0.22 µm filtered solution in PBS with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


## **SDS-PAGE**



SARS-CoV-2 Spike Trimer, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

## **Bioactivity-ELISA**

### **SEC-MALS**




The purity of SARS-CoV-2 Spike Trimer, His Tag (Cat. No. SPN-C52Ha) is more than 90% and the molecular weight of this protein is around 536-593 kDa verified by SEC-MALS.


<u>Report</u>

# SARS-CoV-2 Spike Trimer Protein (T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, D950N), His Tag (MALS verified)


Catalaa # CDN OFOLIa




Immobilized SARS-CoV-2 Spike Trimer, His Tag (Cat. No. SPN-C52Ha) at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-3 ng/mL (QC tested).



Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 5  $\mu$ g/mL (100  $\mu$ L/well) can bind SARS-CoV-2 Spike Trimer, His Tag (Cat. No. SPN-C52Ha) with a linear range of 0.4-13 ng/mL (Routinely tested).



Immobilized SARS-CoV-2 Spike Trimer, His Tag (Cat. No. SPN-C52Ha) at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.1-2 ng/mL (Routinely tested).



Immobilized Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind SARS-CoV-2 Spike Trimer, His Tag (Cat. No. SPN-C52Ha) with a linear range of 0.1-13 ng/mL (Routinely tested).

#### **Background**

It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

## **Clinical and Translational Updates**

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.